| Budget Amount *help |
¥18,590,000 (Direct Cost: ¥14,300,000、Indirect Cost: ¥4,290,000)
Fiscal Year 2009: ¥5,330,000 (Direct Cost: ¥4,100,000、Indirect Cost: ¥1,230,000)
Fiscal Year 2008: ¥5,330,000 (Direct Cost: ¥4,100,000、Indirect Cost: ¥1,230,000)
Fiscal Year 2007: ¥7,930,000 (Direct Cost: ¥6,100,000、Indirect Cost: ¥1,830,000)
|
|---|
| Research Abstract |
It is revealed by our preliminary analysis that serum level of matrix extracellular phosphoglycoprotein (MEPE) that is one of osteocyte-specific-proteins is correlated with the multiplicity of osteoporotic vertebral fracture. However, the amino sequence analysis of MEPE derived fragment present in serum using monoclonal antibodies against MEPE revealed that mAb also bind with the unknown peptide derived from some protein other than MEPE. Identification of this foreign peptide is unfortunately too difficult due to its small amount and the cross reactivity itself in mAb, so clinical application of ELISA using mAb against MEPE has not been established. However, our in vitro study confirmed that the possible importance of the measurement of osteocyte-specific protein and showed the next target protein for development of clinically applicable plasma concentration measurement.
|
